Bullish & Foolish
Full INKT fundamentals All 466 on the Survival Watch

INKTMiNK Therapeutics, Inc.

Is MiNK Therapeutics struggling financially?

Yes, by its own account. MiNK Therapeutics told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

30/100

Fragile

Sector
Biotech/Pharma
Market cap
$62.3M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 7months

    If the burn speeds up

    Empty by Jan 2027

  • 11months

    If it eases off

    Empty by May 2027

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$8.8M

÷

Cash burned over the last 12 months

$11.5M

What MiNK Therapeutics told the SEC

…statements were issued. Because the completion of anticipated funding is not entirely within the Company’s control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q. The financial statements have been prepared on a basis that assumes MiNK will continue as a…

MiNK Therapeutics, Inc., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 23.6% share-count increase The company issued stock. Each share now owns 19.1% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt